In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asphelia Pharmaceuticals Inc.

Latest From Asphelia Pharmaceuticals Inc.

Coronado gets $25.8 million boost to pursue parasite-based autoimmune disease therapy

Coronado Biosciences is out to help prove that mom is not always right when it comes to cleanliness, and investors, led by National Securities, were willing to give the New York-based biotech $25.8 million to back that up.

Gastrointestinal Metabolic Disorders

Asphelia Pharmaceuticals Inc.

In an era of high-tech medicine, of painstakingly designed molecular inhibitors and personalized medicine driven by genetic responses to drugs, Asphelia Pharmaceuticals is placing its bets on a primitive technology: intestinal worms, known as helminthes. Helminthes release proteins that boost the activity of regulatory T-cells, and the antigens they produce appear to influence a variety of targets. Asphelia is developing helminthes as an oral treatment for Crohn's and other autoimmune diseases. Also in the company's pipeline, a novel oral compound that targets integrins in order to treat immunological and inflammatory disorders.

Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Against Inflammation," features profiles of Asphleia Pharmaceuticals, Calistoga Pharmaceuticals, ProtAb Ltd., and Resolvyx Pharmaceuticals. Plus these Start-Ups Across Health Care: CG Therapeutics, Healionics, Mpathy Medical Devices and Pronostics.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Asphelia Pharmaceuticals Inc.
  • Senior Management
  • Francois-Xavier Frapaise, MD, Pres. & CEO
  • Contact Info
  • Asphelia Pharmaceuticals Inc.
    Phone: (858) 731-8520
    4365 Executive Dr.
    Ste. 1500
    San Diego , CA 92121